222 related articles for article (PubMed ID: 11221828)
1. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth.
Liu N; Lapcevich RK; Underhill CB; Han Z; Gao F; Swartz G; Plum SM; Zhang L; Green SJ
Cancer Res; 2001 Feb; 61(3):1022-8. PubMed ID: 11221828
[TBL] [Abstract][Full Text] [Related]
2. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
3. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
4. Goniodomin A, an antifungal polyether macrolide, exhibits antiangiogenic activities via inhibition of actin reorganization in endothelial cells.
Abe M; Inoue D; Matsunaga K; Ohizumi Y; Ueda H; Asano T; Murakami M; Sato Y
J Cell Physiol; 2002 Jan; 190(1):109-16. PubMed ID: 11807817
[TBL] [Abstract][Full Text] [Related]
5. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities.
Sheu JR; Fu CC; Tsai ML; Chung WJ
Anticancer Res; 1998; 18(6A):4435-41. PubMed ID: 9891506
[TBL] [Abstract][Full Text] [Related]
6. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
Ojo-Amaize EA; Nchekwube EJ; Cottam HB; Bai R; Verdier-Pinard P; Kakkanaiah VN; Varner JA; Leoni L; Okogun JI; Adesomoju AA; Oyemade OA; Hamel E
Cancer Res; 2002 Jul; 62(14):4007-14. PubMed ID: 12124334
[TBL] [Abstract][Full Text] [Related]
7. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
8. A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis.
Xu XM; Chen Y; Chen J; Yang S; Gao F; Underhill CB; Creswell K; Zhang L
Cancer Res; 2003 Sep; 63(18):5685-90. PubMed ID: 14522884
[TBL] [Abstract][Full Text] [Related]
9. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
Béliveau R; Gingras D; Kruger EA; Lamy S; Sirois P; Simard B; Sirois MG; Tranqui L; Baffert F; Beaulieu E; Dimitriadou V; Pépin MC; Courjal F; Ricard I; Poyet P; Falardeau P; Figg WD; Dupont E
Clin Cancer Res; 2002 Apr; 8(4):1242-50. PubMed ID: 11948139
[TBL] [Abstract][Full Text] [Related]
10. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells.
Larsson H; Sjöblom T; Dixelius J; Ostman A; Ylinenjärvi K; Björk I; Claesson-Welsh L
Cancer Res; 2000 Dec; 60(23):6723-9. PubMed ID: 11118058
[TBL] [Abstract][Full Text] [Related]
12. FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis.
Sola F; Farao M; Ciomei M; Pastori A; Mongelli N; Grandi M
Invasion Metastasis; 1995; 15(5-6):222-31. PubMed ID: 8765197
[TBL] [Abstract][Full Text] [Related]
13. Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities.
Doñate F; Juarez JC; Guan X; Shipulina NV; Plunkett ML; Tel-Tsur Z; Shaw DE; Morgan WT; Mazar AP
Cancer Res; 2004 Aug; 64(16):5812-7. PubMed ID: 15313924
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
15. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic activity of the purine analog 6-thioguanine.
Presta M; Belleri M; Vacca A; Ribatti D
Leukemia; 2002 Aug; 16(8):1490-9. PubMed ID: 12145690
[TBL] [Abstract][Full Text] [Related]
18. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
Miao WM; Seng WL; Duquette M; Lawler P; Laus C; Lawler J
Cancer Res; 2001 Nov; 61(21):7830-9. PubMed ID: 11691800
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
Bequet-Romero M; Ayala M; Acevedo BE; Rodríguez EG; Ocejo OL; Torrens I; Gavilondo JV
Angiogenesis; 2007; 10(1):23-34. PubMed ID: 17273909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
